Abstract |
Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens.
|
Authors | Morten Orebo Holmström, Hans Carl Hasselbalch, Mads Hald Andersen |
Journal | Oncoimmunology
(Oncoimmunology)
2017
Vol. 6
Issue 11
Pg. e1358334
ISSN: 2162-4011 [Print] United States |
PMID | 29147619
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|